Metabolomics Core The DRC Metabolomics Core provides rigorous mass spectrometry (MS) analyses to DRC Investigators that include quantification as well as structural characterization of diabetes-related biomolecules. The Core increases efficiency and cost effectiveness by providing centralized, standardized analyses to study molecular mechanisms of the pathogenesis of diabetes, its risk factors, and its complications. A major goal of the core is to promote use of MS methods in diabetes research by efforts in training, collaboration, development, service, and dissemination. Specific objectives of the Core are: 1) to provide and maintain functional MS systems for diabetes-related studies; 2) to consult with DRC investigators on application of MS to advance their research programs; 3) to perform service-related MS analyses for diabetes investigators, such as quantifying target analytes, obtaining spectra for structural identification, and assisting with mass spectra interpretation; 4) to develop new MS methods; and 5) to provide training to students and fellows in principles and use of MS systems. The services offered by the Metabolomics Core reflect the evolving bioanalytical needs of DRC investigators, including targeted metabolomic services to broadly survey multiple metabolic pathways and quantify pathway metabolites, in addition to high-throughput, quality-controlled measurements of analytes in large sample sets from clincal studies.
Metabolomics Core Diabetes-related research requires the ability to analyze molecules reflecting the metabolism of glucose, cholesterol, fatty acids, and other key mediators of diabetes and its complications. The DRC Metabolomics Core provides DRC members with access to equipment and expertise allowing characterization of relevant metabolic pathways and quantification of important metabolites relevant to diabetes. The goal of the Metabolomics Core is to promote use of sophisticated analytical methods in diabetes research through support of training, collaboration, development, service, and dissemination.
| Riek, Amy E; Oh, Jisu; Darwech, Isra et al. (2018) Vitamin D3 supplementation decreases a unique circulating monocyte cholesterol pool in patients with type 2 diabetes. J Steroid Biochem Mol Biol 177:187-192 |
| Musselman, Laura Palanker; Fink, Jill L; Maier, Ezekiel J et al. (2018) Seven-Up Is a Novel Regulator of Insulin Signaling. Genetics 208:1643-1656 |
| Bittel, Adam J; Bohnert, Kathryn L; Reeds, Dominic N et al. (2018) Reduced Muscle Strength in Barth Syndrome May Be Improved by Resistance Exercise Training: A Pilot Study. JIMD Rep : |
| Peterson, Linda R; Xanthakis, Vanessa; Duncan, Meredith S et al. (2018) Ceramide Remodeling and Risk of Cardiovascular Events and Mortality. J Am Heart Assoc 7: |
| Ferguson, Daniel; Blenden, Mitchell; Hutson, Irina et al. (2018) Mouse Embryonic Fibroblasts Protect ob/ob Mice From Obesity and Metabolic Complications. Endocrinology 159:3275-3286 |
| Hampton, Kaia K; Anderson, Katie; Frazier, Hilaree et al. (2018) Insulin Receptor Plasma Membrane Levels Increased by the Progesterone Receptor Membrane Component 1. Mol Pharmacol 94:665-673 |
| Warren, Junco S; Tracy, Christopher M; Miller, Mickey R et al. (2018) Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart. Proc Natl Acad Sci U S A 115:E7871-E7880 |
| Samovski, Dmitri; Dhule, Pallavi; Pietka, Terri et al. (2018) Regulation of Insulin Receptor Pathway and Glucose Metabolism by CD36 Signaling. Diabetes 67:1272-1284 |
| Adams, Melissa T; Gilbert, Jennifer M; Hinojosa Paiz, Jesus et al. (2018) Endocrine cell type sorting and mature architecture in the islets of Langerhans require expression of Roundabout receptors in ? cells. Sci Rep 8:10876 |
| Funk, Steven D; Bayer, Raymond H; Malone, Andrew F et al. (2018) Pathogenicity of a Human Laminin ?2 Mutation Revealed in Models of Alport Syndrome. J Am Soc Nephrol 29:949-960 |
Showing the most recent 10 out of 654 publications
